Abstract 43P
Background
Endometrial cancer (EC) is one of the most frequent gynaecological malignant diseases whose incidence presents an increasing trend. Cancer stem cells (CSC), a subpopulation of undifferentiated tumour cells identified in EC, are the main actors in the resistance mechanisms to conventional therapies. Thus, the main aim of this study is to identify novel molecular targets in endometrial CSC for the future development of innovative targeted therapies for EC.
Methods
Two EC cell lines, ECC-1 and RL95-2, were cultured, and endometrial CSC were obtained through an optimized 5-day sphere formation assay. A proteomic profile of cell lines and endometrial CSC was determined through mass spectrometry-based proteomics. The analysis was performed through the comparison of CSC vs. cell line proteins significantly up-regulated by a 40-fold change and their cellular localization. R package was used for statistical analysis.
Results
The proteomic analysis of ECC-1 samples allowed the identification of 477 up-regulated ECC-1-CSC-specific proteins, 108 ECC-1-specific proteins, and 2306 common proteins. Regarding RL95-2 samples, the analysis identified 76 up-regulated RL95-2-CSC-specific, 994 cell line-specific, and 1420 common proteins. The cellular localization of up-regulated proteins identified from CSC populations was mainly the cytoplasm (25-31%), nucleus (19-23%), and membrane (21-22%). Regarding the functional analysis, the more regulated subcategories were the intracellular ferritin complex, poly(A) RNA binding, (acetyl-CoA carboxylase) kinase activity, (hydroxymethylglutaryl-CoA reductase (NADPH)) kinase activity, and ubiquitinyl hydrolase activity for ECC-1-CSC vs. ECC-1; the proteasome, cytosol, extracellular vesicular exosome, poly(A) RNA binding, glutamate dehydrogenase (NAD+) activity, and glutamate dehydrogenase (NADP+) activity for RL95-2-CSC vs. RL95-2; and poly(A) RNA binding, (acetyl-CoA carboxylase) kinase activity, NADPH kinase activity, and ubiquitinyl hydrolase activity for both.
Conclusions
CSC population-specific proteins were identified, as well as their cellular localization and functional enrichment. This information allows for the future development of endometrial CSC targeted therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Univ Coimbra.
Funding
Centre for Innovative Biomedicine and Biotechnology (CIBB) (UIDB/04539/2020, UIDP/04539/2020) is supported by The Fundação para a Ciência e a Tecnologia (FCT), co-funded by COMPETE. Beatriz Serambeque was awarded a PhD Scholarship from FCT and European Social Fund (2020.07672. BD ).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09